Yale Early Stage Ovarian Cancer Detection Technology Licensed By LabCorp®

Main Category: Ovarian Cancer
Also Included In: Medical Devices / Diagnostics;  Regulatory Affairs / Drug Approvals
Article Date: 26 Feb 2006 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

4.75 (4 votes)

Healthcare Prof:not yet rated


New Haven, Conn. -- Yale University Office of Cooperative Research today announced that it has granted an exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of the university's blood testing technology for epithelial ovarian cancer (EOC).

In the United States, EOC is the fourth most common cancer in women, and the leading cause of gynecologic cancer death. EOC affects approximately 25,000 women each year, and more than 16,000 will die from the disease.

The Yale technology for EOC is based on a collection of known serum proteins associated with cancer biology. Each protein marker is analyzed using a routine ELISA assay, and the results evaluated using a score system.

Research, led by Gil Mor, MD, associate professor of obstetrics, gynecology and reproductive sciences at Yale, was published on the technology in 2005. Statistical analyses on preliminary sample sets of a population of 206 women, including 24 patients with early stage (I/II) EOC and 76 with later stage (III/IV) EOC, showed a higher sensitivity and specificity than currently available tests, as well as a positive predictive value. Yale expects to conduct additional clinical studies on the test technology prior to its commercial introduction by LabCorp.

"Ovarian cancer is one of the most difficult cancers to detect, especially in the earliest stages when it is more treatable," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp. "LabCorp continues to dedicate resources to identifying and commercializing tests to help discriminate earlier between disease-free and cancer patients."

###

More information about LabCorp is available online at http://www.labcorp.com/. The Yale University Office of Cooperative Research (YU-OCR) manages the intellectual assets created at Yale. Information on licensing agreements is available through ocr@yale.edu or at http://www.yale.edu/ocr/

Citation: Proc Natl Acad Sciences, 102(21) May 24, 2005.

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
Yale University

Article adapted by Medical News Today from original press release.
Visit our ovarian cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Janet Rettig Emanuel. "Yale Early Stage Ovarian Cancer Detection Technology Licensed By LabCorp®." Medical News Today. MediLexicon, Intl., 26 Feb. 2006. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/38370.php>

APA
Janet Rettig Emanuel. (2006, February 26). "Yale Early Stage Ovarian Cancer Detection Technology Licensed By LabCorp®." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/38370.php.

Please note: If no author information is provided, the source is cited instead.


Ovarian Cancer

Most Popular Articles



Follow Our Ovarian Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Ovarian Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »